acad conf call
You can get the numbers from the ER. In the narative it is clear Daybue is doing
outstanding in the real world . Persistence is good, insurance is growing
with delays by insurer to see how it helps,but growing. Nuplazid stable and
gaining some market share. Pipeline progressing to P2/3 by end of year. Daydue
is the story for now and Europe is yet to gear up.